Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SDG vs ABCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: SDG 0 – 5 ABCL (1 Tie) Matrix Metrics: SDG 1 – 9 ABCL

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over iShares Trust iShares MSCI Global Sustainable Development Goals ETF (SDG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SDG carries a Unified Composite Score of 45.9/100 (HOLD) at $85.63 (N/M Forward P/E, N/A operating margin), whereas ABCL carries 63.5/100 (BUY) at $11.12 (27.6x Forward P/E, -1550.0% operating margin).

  • Technical & Structure Timing Caution: SDG is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.5); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SDG vs ABCL
SDG NASDAQ
iShares Trust iShares MSCI Global Sustainable Development Goals ETF
Institutional Equity
$85.63
-0.81% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.84β · 15% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 38.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.6%) with fading momentum, RSI 41
RSI-14: 40.5 · SMA20: $86.99 · SMA50: $87.70
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.12
-3.22% 1D
Market Cap $3.8B
TTM Revenue $66M
Forward P/E 27.6x
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
63.5 / 100 BUY
Tech 57.0 Fund 59.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.9 · SMA20: $12.04 · SMA50: $12.33

6-Pillar Scorecard Institutional Category Breakdown (SDG 0 – 5 ABCL)

Columns: Metric · SDG · ABCL
1. Valuation Multiples ABCL
Forward P/E N/M 27.6x
Trailing P/E N/M 27.6x
PEG Ratio N/M N/M
EV / Revenue N/M 56.3x
2. Growth & Scale ABCL
Revenue Growth (YoY) N/A -76.3%
Earnings Growth (YoY) N/A +45.9%
TTM Revenue (USD) N/A $66M
Market Cap N/A $3.8B
3. Profitability & Quality ABCL
Gross Margin N/A N/A
Operating Margin N/A -1550.0%
Net Profit Margin N/A -248.8%
Return on Equity (ROE) N/A -17.3%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) N/A -$33M
Cash Flow Margin N/A -49.6%
Net Cash / Leverage N/A ROE $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 84.0% (29th %ile)
Put/Call OI Skew N/A 0.23x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SDG (1) vs ABCL (9)
Institutional Metric SDG ABCL Criterion Row Edge
Market Capitalization
Scale
N/A $3.8B Larger Scale ABCL
Trailing P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY)
Growth
N/A -76.3% Higher Growth ABCL
Operating Margin (TTM)
Profitability
N/A -1550.0% Higher Margin ABCL
Net Profit Margin
Profitability
N/A -248.8% Higher Margin ABCL
Return on Equity (ROE)
Capital Efficiency
N/A -17.3% Higher ROE ABCL
52-Week Range Position
Momentum
38% ($80–$94) 68% ($3–$15) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
0.84β · 15% Vol 2.30β · 87% Vol Lower Realized Risk SDG
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD) 63.5 / 100 (BUY) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
N/A $66M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 56.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$33M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SDG +5.45 pp
SDG: -0.31% · ABCL: -5.76%
3M Horizon ABCL +6.86 pp
SDG: -6.86% · ABCL: +0.0%
6M Horizon ABCL +171.78 pp
SDG: -4.47% · ABCL: +167.31%
1Y Horizon ABCL +207.12 pp
SDG: +0.06% · ABCL: +207.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SDG vs ABCL. Trailing 12-month operating profitability (SDG N/A vs ABCL -1550.0%) and valuation multiples (SDG N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

SDG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$66M
Gross MarginN/A
Op. Margin-1550.0%
ROE / Fwd P/E-17.3% · 27.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SDG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SDG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABCL CONSOLIDATION
34d in phase · OBV NEUTRAL
Current IV 84.0%
IV Percentile 29th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SDG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SDG vs ABCL Key Questions & Quantitative Answers

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over iShares Trust iShares MSCI Global Sustainable Development Goals ETF (SDG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SDG carries a Unified Composite Score of 45.9/100 (HOLD) at $85.63 (N/M Forward P/E, N/A operating margin), whereas ABCL carries 63.5/100 (BUY) at $11.12 (27.6x Forward P/E, -1550.0% operating margin). Technical & Structure Timing Caution: SDG is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.5); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: SDG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABCL at -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin). On trailing 12-month operating scale, SDG generates N/A in USD-normalized revenue versus $66M for ABCL. In operating R&D and SG&A reinvestment, SDG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.

ABCL screens cheaper on headline valuation multiples. SDG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.3x EV/Revenue (-49.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SDG (N/A ROE) versus ABCL (-17.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SDG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 15% Vol realized risk). By comparison, ABCL carries 84.0% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.30β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

iShares Trust iShares MSCI Global Sustainable Development Goals ETF (SDG) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.